Skip to main content

Table 2 General features of the trials which were included

From: Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials

Trials No of patients treated by rivaroxaban (n) No of patients in the placebo group (n) Time period of patients’ enrollment Bias risk score
ATLAS-ACS 2 TIMI 51 10,229 5113 2008–2011 10
GEMINI-ACS-1 1519 1518 2015–2016 10
COMPASS 9152 9126 2013–2016 10
ATLAS-ACS-TIMI 46 2331 1160 2006–2008 10
Total no of patients (n) 23,231 16,917